- Research article
- Open Access
- Open Peer Review
The early response of renal cell carcinoma to tyrosine kinase inhibitors evaluated by FDG PET/CT was not influenced by metastatic organ
- Manabu Kakizoe1,
- Masahiro Yao1,
- Ukihide Tateishi2,
- Ryogo Minamimoto2,
- Daiki Ueno1,
- Kazuhiro Namura1,
- Kazuhide Makiyama1,
- Narihiko Hayashi1,
- Futoshi Sano1,
- Takeshi Kishida3,
- Kazuki Kobayashi4,
- Sumio Noguchi4,
- Ichiro Ikeda5,
- Yoshiharu Ohgo6,
- Masataka Taguri7,
- Satoshi Morita8,
- Tomio Inoue2,
- Yoshinobu Kubota1 and
- Noboru Nakaigawa1Email author
© Kakizoe et al.; licensee BioMed Central Ltd. 2014
- Received: 22 December 2013
- Accepted: 28 May 2014
- Published: 2 June 2014
Tyrosine kinase inhibitors (TKIs) have become the mainstay of treatment for advanced renal cell carcinoma (RCC), but it has been unclear whether the antitumor effect of TKIs depends on the organ where the RCC metastasis is located. We previously reported that the FDG accumulation assessed by FDG PET/CT, was a powerful index for evaluating the biological response to TKI. In this study we investigated the differences in FDG accumulation and the response to TKI as assessed by FDG PET/CT among various organs where RCC were located.
A total of 48 patients with advanced RCC treated with a TKI (25 with sunitinib and 23 with sorafenib) were evaluated by FDG PET/CT before and at 1 month after a TKI treatment initiation. The maximum standardized uptake value (SUVmax) of all RCC lesions were measured and analyzed.
We evaluated 190 RCC lesions. The pretreatment SUVmax values (mean ± SD) were as follows: in the 49 lung metastases, 4.1 ± 3.3; in the 40 bone metastases, 5.4 ± 1.6; in the 37 lymph node metastases, 6.7 ± 2.7; in the 29 abdominal parenchymal organ metastases, 6.6 ± 2.7; in the 26 muscle or soft tissue metastases, 4.4 ± 2.6; and in the nine primary lesions, 8.9 ± 3.9. Significant differences in the SUVmax were revealed between metastases and primary lesions (p = 0.006) and between lung metastases and non-lung metastases (p < 0.001). The SUVmax change ratios at 1 month after TKI treatment started were -14.2 ± 48.4% in the lung metastases, -10.4 ± 23.3% in the bone metastases, -9.3 ± 47.4% in the lymph node metastases, -24.5 ± 41.7% in the abdominal parenchymal organ metastases, -10.6 ± 47.4% in the muscle or soft tissue metastases, and -24.2 ± 18.3% in the primary lesions. There was no significant difference among the organs (p = 0.531).
The decrease ratio of FDG accumulation of RCC lesions evaluated by PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located. This result suggests that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.
- Renal cell carcinoma
- Tyrosine kinase inhibitor
- FDG PET/CT
- Standardized uptake value
Renal cell carcinomas (RCCs) account for 3% of all malignancies in adults . Approximately 30% of RCC patients have metastases at the time of diagnosis, and 20%–40% of all patients relapse or develop metastases after radical nephrectomy with curative intent [2, 3]. For many years, classical cytokine therapies had been the only systematic treatments available for advanced RCC, but the response rate to the cytokine therapies was only ~20% [4–6]. The development of novel and effective systematic therapeutics is desirable.
The oncogenic mechanism of RCC was recently elucidated, and agents have been developed that target the relevant biological pathway that has a critical and necessary role in RCC survival or progression. Tyrosine kinase inhibitors (TKIs) such as sunitinib and sorafenib, which target vascular endothelial growth factor (VEGF) receptors, improved the prognosis of patients with advanced RCC [7–9]. The antitumor activity of the TKIs was not cytotoxic, as are the classical antitumor therapeutics, but rather cytostatic, suppressing biological activity by inhibiting angiogenesis. Actually, some RCCs treated with TKIs did not decrease in tumor volume but entered a period of long-term dormancy, without an enlargement of volume or novel metastasis. A new biological marker evaluating the biological activities of RCC would be important if TKIs are to become the mainstay of treatment for advanced RCC.
Based on this concept, we have been investigating the utility of 18 F-2-fluoro-2-deoxyglucose positron emission tomography/computed tomography (FDG PET/CT), which is a useful non-invasive tool to evaluate glucose metabolic status, and reported the possibility of using the standardized uptake value (SUV), a semiquantitative simplified measurement of the tissue FDG accumulation rate, as a biomarker expressing the biological activity of RCC. We reported previously that the maximum SUV (which was the highest SUV in individual patients assessed by pretreatment FDG PET/CT) could predict survival . We then found that the progression-free survivals of patients with RCC showing a ≥ 20% decrease in SUVmax at 1 month after TKI treatment started was longer than that of patients with RCC showing a < 20% decrease in SUVmax . However, it has been unclear whether pretreatment FDG accumulation and its response to TKI were affected by the organs where the RCC metastases were located. In the present study we thus investigated the differences in FDG accumulation and its response to TKI among organs where RCC metastases were located.
We analyzed patients with advanced RCC pathologically diagnosed by prior nephrectomy or biopsy and treated by sunitinib or sorafenib between June 2008 and April 2013 at Yokohama City University hospital and its affiliated hospitals. The patients were initially assessed by conventional imaging techniques (computed tomography [CT], magnet resonance imaging [MRI], or bone scintigraphy) and diagnosed as stage IV or recurrent RCC. Patients with uncontrolled diabetes mellitus (blood glucose level >150 mg/dL) or with other known malignancies, and those treated with therapeutics during the 2 weeks prior to the scan were excluded. The study protocol was approved by the Yokohama City University Institutional Review Board. Written informed consent was obtained from all patients for enrollment in this study and publication of accompanying clinical records and images. The decision for patients to undergo therapy was made before the evaluation by FDG PET/CT.
Sunitinib was administered to each patient orally once a day at the dose of 50 mg in 6-wk cycles consisting of 4 wks of treatment followed by 2 wks without treatment. Oral sorafenib (800 mg) was administered daily. The dose of sunitinib was reduced to 37.5 or 25 mg and that of sorafenib was reduced to 600 or 400 mg according to the patient’s pretreatment general condition or major adverse events during treatment.
FDG PET/CT was performed in all patients before and 1 month after the TKI treatment started. Patients fasted for at least 6 h prior to an intravenous injection of 18F FDG. PET/CT images were obtained using a PET/CT system (Aquiduo 16; Toshiba Medical Systems, Tokyo). PET/CT images were acquired from the top of the head to the mid-thigh at 60 min after an intravenous injection of 2.5 MBq/kg of [18F] FDG. Mean of the time from injection to imaging was 60 min (standard deviation (SD) 6; range 50-84). Mean of FDG dosage was 151 MBq (SD 29; range 91-212). A low-dose non-contrasted CT scan was acquired first and used for attenuation correction. Emission images were acquired in 3-dimensional mode for 2 min per bed position. After PET acquisition, contrast-enhanced CT was performed with a 2-mm slice thickness, 120 kV, 400 mA, 0.5 s/tube rotation, from the top of the head to the mid-thigh, with breath holding. A total of 100 mL of contrast medium (iopamidol) was administered intravenously at a rate of 1.0 mL/s. The scan delay was set at 120 s after starting the injection of contrast material. The patients with a serum creatinine level >1.5 mg/dL were examined without contrast material. Images were reconstructed by attenuation-weighted ordered-subset expectation maximization (OSEM) (four iterations, fourteen subsets, 128 × 128 matrix, with 5-mm Gaussian smoothing). The standardized uptake value (SUV) was determined according to the standard formula, with activity in the volume of interest (VOI) recorded as Bq per mL/injected dose in Bq per total body weight (kg). The maximum SUV (SUVmax) was recorded using the maximum pixel activity within the VOI. Tumor size responses were evaluated by the Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. The VOI was settled to encompass the targets within areas of increased uptake and measured on each slice by two experienced physician, DU and KM who were blinded to clinical data. Discrepancies were resolved by consensus reading. Analysis of FDG uptake in the primary tumor was made with reference to contrast-enhanced CT images to differentiate tumor from physiologic parenchymal and urinary tract.
The Kruskal-Wallis test and the Mann-Whitney U-test were used to assess the differences in pretreatment SUVmax, post-treatment SUVmax, SUVmax change ratio, and the diameter change ratio among organs where RCC metastases were located. In the assessment of the SUVmax change ratio, the RCC metastases which pretreatment FDG accumulations were not detected were excluded. In the assessment of diameter change ratio, the RCC metastases which diameter could not be measured were excluded. All statistical analyses were carried out with SPSS software (SPSS, Chicago, IL). Significance was assigned at p < 0.05.
Patient characteristics and intervention
Patients and disease characteristics (n=48)
Prior systematic treatment
Evaluated RCC lesions
According to the Memorial Sloan-Kettering Cancer Center (MSKCC) classification , 17 patients were classified as favorable risk, 24 as intermediate risk, and 7 as poor risk. Thirty-eight patients had undergone nephrectomy. Thirty patients had had no previous systematic therapies, and 18 patients had previous systematic therapies (one with sunitinib, one with sorafenib, two with sorafenib and interferon-alpha, 10 with interferon alpha, and 2 with interferon alpha and interleukin-2, 2 with chemotherapy). These treatments ended more than 2 wks prior to the pretreatment evaluation by FDG PET/CT.
In the 48 patients, we analyzed 190 RCC lesions diagnosed as RCC tumors by conventional imaging techniques. The numbers of RCC lesions in individual patients ranged from one to 10 (median three). There were 49 lung metastases (25.8%), 40 bone metastases (21.0%), 37 lymph node metastases (19.5%), 29 abdominal organ metastases including liver, adrenal gland, pancreas, spleen, contralateral kidney, uterus, and vagina (15.3%), 26 muscle or soft tissue metastases (13.7%), and nine renal primary sites (4.7%).
The assessment by FDG PET/CT
We next analyzed the SUVmax assessed by FDG PET/CT performed 1 month after the TKI treatment initiation (day 30 ± 6; range 14 to 47). The post-treatment SUVmax of all 190 lesions was 4.6 ± 2.9 (mean ± SD). The post-treatment SUVmax values were: lung metastases 3.5 ± 3.0 , bone metastases 4.9 ± 2.2, lymph node metastases 5.6 ± 3.1, abdominal organ metastases 4.6 ± 2.8, muscle or soft tissue metastases 3.6 ± 2.5, and primary sites 6.6 ± 3.0, with a significant difference (p = 0.001, Kruskal-Wallis test) (Figure 1). The mean of post-treatment SUVmax in all metastases was 4.5 ± 2.8, and there was a significant difference in SUVmax between primary sites and metastases (p = 0.034, Mann-Whitney U-test). When the differences among metastasis locations were analyzed, the lung metastases demonstrated significantly lower SUVmax values compared to the non-lung metastases (p = 0.014, Mann-Whitney U-test).
We and some other investigators have found that FDG PET/CT is a powerful tool to assess the biological status of RCCs, and we suggested the potency of FDG PET/CT as an imaging biomarker for advanced RCC [10, 11, 13–16]. One of the uses of an imaging biomarker is to evaluate individual lesions in a single patient. Gerlinger et al. reported that the gene-expression signature of RCC showed heterogeneity, for example between metastases and the primary lesion in an individual patient . Their findings suggested that the biological evaluation of individual metastases of RCC in a single patient was important, but at the same time their report raised many clinical questions. One of the questions was whether the biological status of an RCC and its response to treatment are influenced by the organ at which the RCC metastasis is located. Here we investigated the differences among organs where RCC metastases were located using the assessments by FDG PET/CT.
We first focused on the differences in pretreatment FDG accumulation among the organ where RCC metastases were located. The primary origin showed higher pretreatment FDG accumulation compared to the metastases. Additionally, the lung metastases showed lower accumulation compared to non-lung metastases when the difference in FDG accumulation among only metastases was examined, although there was not statistical difference in the diameter between the lung metastases and non-lung metastases (data not shown). The present results support our hypothesis that the FDG accumulation expressed biological activity of RCC and RCCs showing high FDG accumulation predict a short survival time. Because, there are several clinical reports that the prognosis of RCC patients with primary tumors was poor compared with that of patients who had undergone a nephrectomy [18–20]. Additionally, lung metastases showed the better response to various therapies than non-lung metastasis and RCC patients with lung metastasis only show longer survival than other RCC patients [21–24]. In our study, there were only 2 patients with only lung metastasis. The difference of prognosis cannot be analyzed in such small sized study. The further study targeting large number of patients is necessary.Next, we focused on the change of FDG accumulation at 1 month after TKI treatment started, and we found that the change ratio of FDG accumulation was not significantly different among the organs where RCC metastases were located. However, the change ratio of SUVmax in the 190 lesions evaluated in this study showed a wide range (median -16%, range -100 to 137). An interesting finding of the present study was that the change ratio of FDG accumulation of the bone metastases was not significantly different from that of the none-bone metastases, although the sizes of the bone metastases did not reduce like that of the non-bone metastases did, as shown in Figures 2 and 3. Actually, the patient whose case is shown in Figure 4B, with bone metastasis showing a 28% decrease in the SUVmax after sunitinib treatment started, is alive with disease on the last observation, 40 months after the treatment started. These results indicate that the delivery and effect of TKIs are not influenced by the organ location of RCC metastasis, and they suggest that TKIs could be applied for patients with advanced RCC regardless of the metastatic site.
To our knowledge, this is the first report to analyze the differences in FDG accumulation of RCC among metastases locations. However, the number of patients was limited. A further study with a larger number of patients is necessary to test these results.
The decrease ratio of FDG accumulation of RCC lesions evaluated by FDG PET/CT at 1 month after TKI treatment initiation was not influenced by the organs where the RCC metastasis was located. This result suggests that TKIs can be used to treat patients with advanced RCC regardless of the metastatic site.
This work was supported by Grants-in-Aid for Scientific Research (No. 22591775) from the Ministry of Education, Science, Sports and Culture of Japan.
- Chow WH, Devesa SS, Warren JL, Fraumeni JF: Rising incidence of renal cell carcinoma in the United States. JAMA. 1999, 281: 1628-1631. 10.1001/jama.281.17.1628.View ArticlePubMedGoogle Scholar
- Linehan WM, Walther MM, Alexander RB, Rosenberg SA: Adoptive immunotherapy of renal cell carcinoma: studies from the Surgery Branch, National Cancer Institute. Semin Urol. 1993, 11: 41-43.PubMedGoogle Scholar
- Janzen NK, Kim HL, Figlin RA, Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 2003, 30: 843-852. 10.1016/S0094-0143(03)00056-9.View ArticlePubMedGoogle Scholar
- McDermott DF, Regan MM, Clark JI, Flaherty LE, Weiss GR, Logan TF, Kirkwood JM, Gordon MS, Sosman JA, Ernstoff MS, Tretter CP, Urba WJ, Smith JW, Margolin KA, Mier JW, Gollob JA, Dutcher JP, Atkins MB: Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol. 2005, 23: 133-141. 10.1200/JCO.2005.03.206.View ArticlePubMedGoogle Scholar
- Yang JC, Sherry RM, Steinberg SM, Topalian SL, Schwartzentruber DJ, Hwu P, Seipp CA, Rogers-Freezer L, Morton KE, White DE, Liewehr DJ, Merino MJ, Rosenberg SA: Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol. 2003, 21: 3127-3132. 10.1200/JCO.2003.02.122.View ArticlePubMedPubMed CentralGoogle Scholar
- Negrier S, Escudier B, Lasset C, Douillard JY, Savary J, Chevreau C, Ravaud A, Mercatello A, Peny J, Mousseau M, Philip T, Tursz T: Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma: Groupe Français D’Immunotherapie. N Engl J Med. 1998, 338: 1272-1278. 10.1056/NEJM199804303381805.View ArticlePubMedGoogle Scholar
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Rixe O, Oudard S, Negrier S, Szczylik C, Kim ST, Chen I, Bycott PW, Baum CM, Figlin RA: Sunitinib versus interferon alfa in metastatic renal cell carcinoma. N Engl J Med. 2007, 356: 115-124. 10.1056/NEJMoa065044.View ArticlePubMedGoogle Scholar
- Escudier B, Eisen T, Stadler WM, Szczylik C, Oudard S, Siebels M, Negrier S, Chevreau C, Solska E, Desai AA, Rolland F, Demkow T, Hutson TE, Gore M, Freeman S, Schwartz B, Shan M, Simantov R, Bukowski RM, TARGET Study Group: Sorafenib in advanced clear cell renal cell carcinoma. N Engl J Med. 2007, 356: 125-134. 10.1056/NEJMoa060655.View ArticlePubMedGoogle Scholar
- Motzer RJ, Hutson TE, Tomczak P, Michaelson MD, Bukowski RM, Oudard S, Negrier S, Szczylik C, Pili R, Bjarnason GA, Garcia-del-Muro X, Sosman JA, Solska E, Wilding G, Thompson JA, Kim ST, Chen I, Huang X, Figlin RA: Overall survival and updated results for sunitinib versus interferon alfa in the first-line toreatment of patients with metastatic renal cell carcinoma. J Clin Oncol. 2009, 27: 3584-3590. 10.1200/JCO.2008.20.1293.View ArticlePubMedPubMed CentralGoogle Scholar
- Namura K, Minamimoto R, Yao M, Makiyama K, Murakami T, Sano F, Hayashi N, Tateishi U, Ishigaki H, Kishida T, Miura T, Kobayashi K, Noguchi S, Inoue T, Kubota Y, Nakaigawa N: Impact of maximum standardized uptake value (SUVmax) evaluated by 18-Fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography (18 F-FDG-PET/CT) on survival for patients with advanced renal cell carcinoma: a preliminary report. BMC Cancer. 2010, 10: 667-10.1186/1471-2407-10-667.View ArticlePubMedPubMed CentralGoogle Scholar
- Ueno D, Yao M, Tateishi U, Minamimoto R, Makiyama K, Hayashi N, Sano F, Murakami T, Kishida T, Miura T, Kobayashi K, Noguchi S, Ikeda I, Ohgo Y, Inoue T, Kubota Y, Nakaigawa N: Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course. BMC Cancer. 2012, 12: 162-10.1186/1471-2407-12-162.View ArticlePubMedPubMed CentralGoogle Scholar
- Motzer RJ, Bacik J, Murphy BA, Russo P, Mazumdar M: Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol. 2002, 20: 289-296. 10.1200/JCO.20.1.289.View ArticlePubMedGoogle Scholar
- Minamimoto R, Nakaigawa N, Tateishi U, Suzuki A, Shizukuishi K, Kishida T, Miura T, Makiyama K, Yao M, Kubota Y, Inoue T: Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhnced CT. Clin Nucl Med. 2010, 35: 918-923. 10.1097/RLU.0b013e3181f9ddd9.View ArticlePubMedGoogle Scholar
- Vercellino L, Bousquet G, Baillet G, Barré E, Mathieu O, Just PA, Desgrandchamps F, Misset JL, Hindié E, Moretti JL: 18 F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study. Cancer Biother Radiopharm. 2009, 24: 137-144. 10.1089/cbr.2008.0527.View ArticlePubMedGoogle Scholar
- Lyrdal D, Boijsen M, Suurküla M, Lundstam S, Stierner U: Evaluation of sorafenib treatment in metastatic renal cell carcinoma with 2-fluoro-2deoxyglucose positron emission tomography and computed tomography. Nucl Med Commun. 2009, 30: 519-524. 10.1097/MNM.0b013e32832cc220.View ArticlePubMedGoogle Scholar
- Kayani I, Avril N, Bomanji J, Chowdhury S, Rockall A, Sahdev A, Nathan P, Wilson P, Shamash J, Sharpe K, Lim L, Dickson J, Ell P, Reynolds A, Powles T: Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer. Clin Cancer Res. 2011, 17: 6021-6028. 10.1158/1078-0432.CCR-10-3309.View ArticlePubMedGoogle Scholar
- Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, Martinez P, Matthews N, Stewart A, Tarpey P, Varela I, Phillimore B, Begum S, McDonald NQ, Butler A, Jones D, Raine K, Latimer C, Santos CR, Nohadani M, Eklund AC, Spencer-Dene B, Clark G, Pickering L, Stamp G, Gore M, Szallasi Z, Downward J, Futreal PA, Swanton C: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 2012, 366: 883-892. 10.1056/NEJMoa1113205.View ArticlePubMedPubMed CentralGoogle Scholar
- Flanigan RC, Mickisch G, Sylvester R, Tangen C, Van Poppel H, Crawford ED: Cytoreductive nephrectomy in patients with metastatic renal cancer: a combined analysis. J Urol. 2004, 171: 1071-1076. 10.1097/01.ju.0000110610.61545.ae.View ArticlePubMedGoogle Scholar
- Motzer RJ, Mazumdar M, Bacik J, Berg W, Amsterdam A, Ferrara J: Survival and prognostic stratification of 670 patients with advanced renal cell carcinoma. J Clin Oncol. 1999, 17: 2530-2540.PubMedGoogle Scholar
- Heng DY, Xie W, Regan MM, Warren MA, Golshayan AR, Sahi C, Eigl BJ, Ruether JD, Cheng T, North S, Venner P, Knox JJ, Chi KN, Kollmannsberger C, McDermott DF, Oh WK, Atkins MB, Bukowski RM, Rini BI, Choueiri TK: Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol. 2009, 27: 5794-5799. 10.1200/JCO.2008.21.4809.View ArticlePubMedGoogle Scholar
- de Kernion JB, Sarna G, Figlin R, Lindner A, Smith RB: The treatment of renal cell carcinoma with human leukocyte alpha-interferon. J Urol. 1983, 130: 1063-1066.Google Scholar
- Akaza H, Kawai K, Tsukamoto T, Fujioka T, Tomita Y, Kitamura T, Ozono S, Miki T, Naito S, Zembutsu H, Nakamura Y: Successful outcomes using combination therapy of interleukin-2 and interferon-alpha for renal cell carcinoma patients with lung metastasis. Jpn J Clin Oncol. 2010, 40: 684-689. 10.1093/jjco/hyq027.View ArticlePubMedGoogle Scholar
- Tsuchiya N, Yuasa T, Maita S, Narita S, Inoue T, Numakura K, Saito M, Satoh S, Yonese J, Habuchi T: Organ-specific and tumor-size-dependent responses to sunitinib in clear cell renal cell carcinoma. BMC Urol. 2014, 14: 26-10.1186/1471-2490-14-26.View ArticlePubMedPubMed CentralGoogle Scholar
- Flanigan RC, Salmon SE, Blumenstein BA, Bearman SI, Roy V, McGrath PC, Caton JR, Munshi N, Crawford ED: Nephrectomy followed by interferon alfa-2b compared with interferon alfa-2b alone for metastatic renal-cell cancer. N Engl J Med. 2001, 345: 1655-1659. 10.1056/NEJMoa003013.View ArticlePubMedGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/14/390/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.